Aimmune Therapeutics’ $176 million Stake Offering

Davis Polk advised the joint book-running managers in connection with a $176 million SEC-registered offering of 5,500,000 shares of common stock of Aimmune Therapeutics, Inc.

BofA Merrill Lynch, Cantor, Piper Jaffray, Credit Suisse, RBC Capital Markets, Roth Capital Partners and Wedbush PacGrow acted as underwriters.

Aimmune Therapeutics is a biopharmaceutical company developing treatments for potentially life-threatening food allergies.

The Davis Polk corporate team included partner Stephen Salmon (Picture) and associates Marcus K. Hintze, Josephine Chen and Dylan Service. The tax team included partner Rachel D. Kleinberg. The intellectual property and technology team included counsel Michelle Ontiveros Gross and associate Jason J. Bang.

Involved fees earner: Stephen Salmon – Davis Polk & Wardwell; Marcus K. Hintze – Davis Polk & Wardwell; Josephine Chen – Davis Polk & Wardwell; Dylan Service – Davis Polk & Wardwell; Rachel Kleinberg – Davis Polk & Wardwell; Michelle Ontiveros Gross – Davis Polk & Wardwell; Jason Bang – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: Bank of America Merrill Lynch; Credit Suisse; RBC Capital Markets; Piper Jaffray & Co; Roth Capital Partners, LLC; Cantor Fitzgerald Securities; Wedbush PacGrow;

Print Friendly, PDF & Email

Author: Ambrogio Visconti